Cargando…
Therapeutic management of hyperlipoproteinemia (a)
Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent major risk factor for the development of CVD, as wel...
Autores principales: | Kosmas, Constantine E, Sourlas, Andreas, Mallarkey, Gordon, Silverio, Delia, Ynoa, Domingo Y, Montan, Peter D, Guzman, Eliscer, Garcia, Mario J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752750/ https://www.ncbi.nlm.nih.gov/pubmed/31555339 http://dx.doi.org/10.7573/dic.212609 |
Ejemplares similares
-
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2019) -
Primary genetic disorders affecting high density lipoprotein (HDL)
por: Kosmas, Constantine E, et al.
Publicado: (2018) -
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
por: Kosmas, Constantine E, et al.
Publicado: (2018) -
Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018) -
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
por: Kosmas, Constantine E., et al.
Publicado: (2023)